You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-PRAME (PRAME) Antibodies

Full name:
anti-Preferentially Expressed Antigen in Melanoma Antibodies (PRAME)
On www.antibodies-online.com are 57 Preferentially Expressed Antigen in Melanoma (PRAME) Antibodies from 14 different suppliers available. Additionally we are shipping PRAME Proteins (12) and PRAME Kits (5) and many more products for this protein. A total of 86 PRAME products are currently listed.
Synonyms:
4930534P07Rik, CT130, MAPE, OIP-4, OIP4, PRAME
list all antibodies Gene Name GeneID UniProt
PRAME 23532 P78395
PRAME 75829  
PRAME 680000  

Show all species

Show all synonyms

All available anti-PRAME Antibodies

Go to our pre-filtered search.

Top referenced anti-PRAME Antibodies

  1. Human Polyclonal PRAME Primary Antibody for EIA, WB - ABIN453177 : Rezvani, Yong, Tawab, Jafarpour, Eniafe, Mielke, Savani, Keyvanfar, Li, Kurlander, Barrett: Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. in Blood 2009 (PubMed)
    Show all 3 references for ABIN453177

  2. Cow (Bovine) Polyclonal PRAME Primary Antibody for WB - ABIN2786466 : Sakakura, Kubo, Ako, Ikeda, Funayama, Hirahara, Sugawara, Yasu, Kawakami, Momomura: Determinants of in-hospital death and rupture in patients with a Stanford B aortic dissection. in Circulation journal : official journal of the Japanese Circulation Society 2007 (PubMed)
    Show all 2 references for ABIN2786466

  3. Human Polyclonal PRAME Primary Antibody for WB - ABIN2786465 : Roman-Gomez, Jimenez-Velasco, Agirre, Castillejo, Navarro, Jose-Eneriz, Garate, Cordeu, Cervantes, Prosper, Heiniger, Torres: Epigenetic regulation of PRAME gene in chronic myeloid leukemia. in Leukemia research 2007 (PubMed)

More Antibodies against PRAME Interaction Partners

Cow (Bovine) Preferentially Expressed Antigen in Melanoma (PRAME) interaction partners

  1. the expansion of the PRAME family occurred in both autosomes and sex chromosomes

Human Preferentially Expressed Antigen in Melanoma (PRAME) interaction partners

  1. PRAME expression is considered as a poor prognostic parameter in HL.

  2. PRAME immunoreactivity in myeloid leukemia (show BCL11A Antibodies) (ML) of Down syndrome (DS) is largely due to the non-blast components, while PRAME immunoreactivity in blasts of Transient abnormal myelopoiesis (TAM (show CCNA1 Antibodies)) is not restricted to cases that progress to ML of DS.

  3. This study shows the prognostic significance of PRAME expression in diffuse large B-cell lymphoma patients treated with R-CHOP (show DDIT3 Antibodies) therapy.

  4. results suggested that PRAME was a predictor for better outcome, could be a useful target for immunotherapy, and might represent a candidate marker for the monitoring of minimal residual disease

  5. elevated PRAME expression in head and neck squamous cell carcinoma

  6. PRAME and WT1 (show WT1 Antibodies) transcripts constitute a good molecular marker combination for monitoring minimal residual disease in MDS (show PAFAH1B1 Antibodies).

  7. PRAME impairs differentiation and increases proliferation likely via blocking retinoic acid receptor (show RARA Antibodies) signaling.

  8. PRAME expression in leukaemic cell lines is upregulated by IFN gamma (show IFNG Antibodies) and LPS (show IRF6 Antibodies), suggesting a possible role in immune responses. PRAME associates with Elongin BC complexes by binding Elongin C (show TCEB1 Antibodies), and co-localises to the Golgi network. Nuclear PRAME interacts with Histone H3 (show HIST3H3 Antibodies). The results suggest that PRAME has dual roles in gene regulation in the nucleus and protein turnover trafficking in the Golgi

  9. The complex PRAME/EZH2 (show EZH2 Antibodies) is able to repress TRAIL expression, in a cancer-specific manner; inhibition of PRAME/EZH2 (show EZH2 Antibodies) releases apoptosis-mediating TRAIL. (Review)

  10. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.

PRAME Antigen Profile

Antigen Summary

This gene encodes an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. Five alternatively spliced transcript variants encoding the same protein have been observed for this gene.

Alternative names and synonyms associated with PRAME

  • preferentially expressed antigen in melanoma (PRAME) antibody
  • preferentially expressed antigen in melanoma (Prame) antibody
  • 4930534P07Rik antibody
  • CT130 antibody
  • MAPE antibody
  • OIP-4 antibody
  • OIP4 antibody
  • PRAME antibody

Protein level used designations for PRAME

preferentially expressed antigen in melanoma , Opa-interacting protein OIP4 , cancer/testis antigen 130 , melanoma antigen preferentially expressed in tumors , opa-interacting protein 4 , preferentially expressed antigen of melanoma

GENE ID SPECIES
528601 Bos taurus
23532 Homo sapiens
785023 Bos taurus
75829 Mus musculus
680000 Rattus norvegicus
Selected quality suppliers for anti-PRAME (PRAME) Antibodies
Did you look for something else?